Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
פורמט:	Article
שפה:	English
יצא לאור:	Elsevier 2023-12-01
סדרה:	Translational Oncology
נושאים:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

פריטים דומים

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
מאת: Hana Garaj, et al.
יצא לאור: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
מאת: Senar Ebinç, et al.
יצא לאור: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
מאת: Wu L, et al.
יצא לאור: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
מאת: Katarina Mirjačić Martinović, et al.
יצא לאור: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
מאת: Dugan MM, et al.
יצא לאור: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
מאת: Polsky David, et al.
יצא לאור: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
מאת: Francesca Consoli, et al.
יצא לאור: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
מאת: Jacek Calik, et al.
יצא לאור: (2024-01-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
מאת: Justin C. Moser, et al.
יצא לאור: (2019-12-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
מאת: Xiang Dan, et al.
יצא לאור: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
מאת: I. V. SAMOILENKO, et al.
יצא לאור: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
מאת: Ernesto Rossi, et al.
יצא לאור: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
מאת: Lance Wollenberg, et al.
יצא לאור: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
מאת: Bartoušková Marie, et al.
יצא לאור: (2020-08-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
מאת: Yu. S. Shakh-Paronyants, et al.
יצא לאור: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
מאת: Dahlia Fedele, et al.
יצא לאור: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
מאת: Saba S. Shaikh, et al.
יצא לאור: (2022-11-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
מאת: Milena Cavic, et al.
יצא לאור: (2023-04-01)

Melanoma: BRAFi Rechallenge
מאת: Christoforos S. Kosmidis, et al.
יצא לאור: (2023-05-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
מאת: Rozala Arko, et al.
יצא לאור: (2022-07-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
מאת: Sarkisian S, et al.
יצא לאור: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
מאת: Lazaro Hiram Betancourt, et al.
יצא לאור: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
מאת: Enrica Teresa Tanda, et al.
יצא לאור: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
מאת: Marco Ghezzi, et al.
יצא לאור: (2020-03-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
מאת: Ahmed Temirak, et al.
יצא לאור: (2025-02-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
מאת: Peter Mohr, et al.
יצא לאור: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
מאת: Karam Khaddour, et al.
יצא לאור: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
מאת: Igor V. Samoylenko, et al.
יצא לאור: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
מאת: Adi Kartolo, et al.
יצא לאור: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
מאת: Simeng Zhang, et al.
יצא לאור: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
מאת: Clara So, et al.
יצא לאור: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
מאת: Julia Kuchnicka, et al.
יצא לאור: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
מאת: Taku Fujimura, et al.
יצא לאור: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
מאת: Elodie Long-Mira, et al.
יצא לאור: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
מאת: Walid Shalata, et al.
יצא לאור: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
מאת: Nakul Dar, et al.
יצא לאור: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
מאת: Lena Groennendijk, et al.
יצא לאור: (2022-06-01)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
מאת: Francesco Serra, et al.
יצא לאור: (2021-08-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
מאת: O. I. Kit, et al.
יצא לאור: (2016-06-01)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
מאת: Sim Vermeulen, et al.
יצא לאור: (2021-04-01)